Research programme: ophthalmologic siRNA therapeutics - SylentisAlternative Names: SYL-040003; SYL-054003
Latest Information Update: 12 Jul 2016
At a glance
- Originator Sylentis
- Class Eye disorder therapies; Gene therapies; Small interfering RNA
- Mechanism of Action TRPV1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glaucoma; Ocular pain